Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights

Journal of Gastroenterology

Volumn 51, Issue 6, 2016, Pages 511-519

  Greuter, Thomas ^a   Shah, Vijay H ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MAYO CLINIC   (United States)

Author keywords

Exosome signaling; Hepatic stellate cell; Intercellular communication; Intrasinusoidal thrombosis; Microvesicles; Sinusoidal epithelial cell

Indexed keywords

ALCOHOL LIVER DISEASE; CELL COMMUNICATION; CONGESTIVE HEPATOPATHY; ENDOTHELIUM CELL; EXOSOME; HEPATITIS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER SINUSOID; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SINUSOIDAL ENDOTHELIAL CELL; STELLATE CELL; CAPILLARY; HEPATIC STELLATE CELL; LIVER DISEASES; PHYSIOLOGY;

CAPILLARIES; CELL COMMUNICATION; ENDOTHELIAL CELLS; HEPATIC STELLATE CELLS; HUMANS; LIVER DISEASES;

EID: 84960126340     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1190-4     Document Type: Review

References (97)

1. Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis—current status and future directions. J Hepatol. 2014;61(4):912–24.
2. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62(1 Suppl):S121–30.
3. Arii S, Imamura M. Physiological role of sinusoidal endothelial cells and Kupffer cells and their implication in the pathogenesis of liver injury. J Hepatobiliary Pancreat Surg. 2000;7(1):40–8.
4. Braet F, De Zanger R, Baekeland M, Crabbé E, Van Der Smissen P, Wisse E. Structure and dynamics of the fenestrae-associated cytoskeleton of rat liver sinusoidal endothelial cells. Hepatology. 1995;21(1):180–9.
5. Hilscher MB, Huebert RC, Shah VH. Hepatic sinusoidal endothelial cells. In: Dufour JD, Clavien PA, editors. Signaling pathways in liver diseases. New York: Wiley; 2015. p. 73–81.
6. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res. 1970;31(1):125–50.
7. Burt AD, Le Bail B, Balabaud C. Morphological investigation of sinusoidal cells. Semin Liver Dis. 1993;13:21–38.
8. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest. 1997;100(11):2923–30.
9. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology. 2015;61(5):1740–6.
10. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol. 2004;287(4):G757–63.
11. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest. 2006;86(1):9–22.
12. Jagavelu K, Routray C, Shergill U, O’Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology. 2010;52(2):590–601.
13. Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012;56(4):893–9.
14. Iwakiri Y, Grisham M, Shah V. Vascular biology and pathobiology of the liver: Report of a single-topic symposium. Hepatology. 2008;47(5):1754–63.
15. Xu B, Broome U, Uzunel M, Nava S, Ge X, Kumagai-Braesch M, et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol. 2003;163(4):1275–89.
16. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology. 1963;44:239–42.
17. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114(2):344–51.
18. Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, et al. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology. 2008;47(6):1983–93.
19. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920–30.
20. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension? J Hepatol. 2010;53(5):976–80.
21. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte? Hepatology. 2007;45(3):817–25.
22. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35(5):1010–21.
23. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130(4):691–703.
24. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007;46(6):1919–26.
25. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol. 2009;157(2):258–70.
26. Caligiuri A, Marra F. Stellate cells. In: Dufour JF, Clavien PA, editors. Signaling pathways in liver diseases. New York: Wiley; 2015. p. 34–52.
27. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol. 2005;39(4 Suppl 2):S158–61.
28. Kent G, Gay S, Inouye T, Bahu R, Minick OT, Popper H. Vitamin A-containing lipocytes and formation of type III collagen in liver injury. Proc Natl Acad Sci USA. 1976;73(10):3719–22.
29. Nakatani T, Honda E, Hayakawa S, Sato M, Satoh K, Kudo M, et al. Effects of decorin on the expression of alpha-smooth muscle actin in a human myofibroblast cell line. Mol Cell Biochem. 2008;308(1–2):201–7.
30. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis. 1999;19(2):129–40.
31. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, et al. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem. 2010;285(41):31840–8.
32. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, et al. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest. 2010;120(7):2379–94.
33. Lai CC, Henningson C, DiMaio D. Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor beta receptor. Proc Natl Acad Sci USA. 1998;95(26):15241–6.
34. Westermark B, Siegbahn A, Heldin CH, Claesson-Welsh L. B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. Proc Natl Acad Sci USA. 1990;87(1):128–32.
35. Claesson-Welsh L, Eriksson A, Morén A, Severinsson L, Ek B, Ostman A, et al. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. Mol Cell Biol. 1988;8(8):3476–86.
36. Michel T, Feron O. Nitric oxide synthases: Which, where, how, and why? J Clin Invest. 1997;100(9):2146–52.
37. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117(5):1222–8.
38. Funyu J, Mochida S, Inao M, Matsui A, Fujiwara K. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys Res Commun. 2001;280(2):481–5.
39. Yokomori H, Oda M, Yoshimura K, Nagai T, Ogi M, Nomura M, et al. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. Liver Int. 2003;23(6):467–75.
40. May D, Djonov V, Zamir G, Bala M, Safadi R, Sklair-Levy M, et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations. PLoS One. 2011;6(7):e21478.
41. Xie G, Wang X, Wang L, Atkinson RD, Kanel GC, Gaarde WA, et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology. 2012;142(4):918–27 (e6).
42. Kwon SH, Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, et al. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma. Clin Mol Hepatol. 2012;18(3):287–94.
43. Liu C, Li J, Xiang X, Guo L, Tu K, Liu Q, et al. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors. Am J Physiol Gastrointest Liver Physiol. 2014;307(7):G749–59.
44. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308–16.
45. Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–53.
46. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology. 2008;135(2):671–9.
47. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology. 2011;54(2):573–85.
48. Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem. 2012;287(10):7190–202.
49. Wang R, Huebert RC, Shah VH. Sinusoidal endothelial cells coordinate liver regeneration and angiogenesis via angiopoietin-2: An ode to prometheus. Gastroenterology. 2014;147(2):533–4.
50. Hu J, Srivastava K, Wieland M, Runge A, Mogler C, Besemfelder E, et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Science. 2014;343(6169):416–9.
51. Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804–11.
52. Asrani SK, Asrani NS, Freese DK, Phillips SD, Warnes CA, Heimbach J, et al. Congenital heart disease and the liver. Hepatology. 2012;56(3):1160–9.
53. Wu FM, Ukomadu C, Odze RD, Valente AM, Mayer JE, Earing MG. Liver disease in the patient with Fontan circulation. Congenit Heart Dis. 2011;6(3):190–201.
54. Baek JS, Bae EJ, Ko JS, Kim GB, Kwon BS, Lee SY, et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart. 2010;96(21):1750–5.
55. Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012;42(2):153–63.
56. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;6(4 Suppl 1):S44–52.
57. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21(5):1238–47.
58. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21(5):1232–7.
59. Moschcowitz E. The morphology and pathogenesis of cardiac fibrosis of the liver. Ann Intern Med. 1952;36(4):933–55.
60. Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: A detailed morphological study. J Clin Pathol. 2008;61(4):504–8.
61. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003;52(8):1206–10.
62. Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46(2):286–94.
63. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: Implications for the development of novel therapies. J Thromb Haemost. 2008;6(8):1336–43.
64. Simonetto DA, Yang HY, Yin M, de Assuncao TM, Kwon JH, Hilscher M, et al. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatology. 2015;61(2):648–59.
65. Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.
66. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101(3):942–8.
67. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;30(3.22):3.22.1–29.
68. Masyuk AI, Masyuk TV, Larusso NF. Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J Hepatol. 2013;59(3):621–5.
69. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820(7):940–8.
70. Bang C, Thum T. Exosomes: new players in cell–cell communication. Int J Biochem Cell Biol. 2012;44(11):2060–4.
71. Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: a web-based compendium of 39 Exosomal Cargo. J Mol Biol. 2015. doi: 10.1016/j.jmb.2015.09.019 (Epub ahead of print).
72. Sun D, Zhuang X, Zhang S, Deng ZB, Grizzle W, Miller D, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65(3):342–7.
73. Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014;5(14):5686–99.
74. Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Wang Q, et al. Intestinal mucus-derived nanoparticle-mediated activation of Wnt/β-catenin signaling plays a role in induction of liver natural killer T cell anergy in mice. Hepatology. 2013;57(3):1250–61.
75. Vokes SA, Yatskievych TA, Heimark RL, McMahon J, McMahon AP, Antin PB, et al. Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. Development. 2004;131(17):4371–80.
76. Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology. 2009;136(1):320–30 (e2).
77. Wang R, Ding Q, Yaqoob U, de Assuncao TM, Verma VK, Hirsova P, et al. Exosome adherence and internalization by hepatic stellate cells triggers sphingosine 1-phosphate dependent migration. J Biol Chem. 2015;290(52):30684–96.
78. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: Current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12(4):555–64 (quiz e31–2).
79. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758–69.
80. Gao B, Shah VH. Combination therapy: New hope for alcoholic hepatitis? Clin Res Hepatol Gastroenterol. 2015;39(Suppl 1):S7–11.
81. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem. 2010;391(11):1249–64.
82. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis. 2014;5:e996.
83. Szabo G. Gut–liver axis in alcoholic liver disease. Gastroenterology. 2015;148(1):30–6.
84. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–24.
85. Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146(5):1231–9 (e1–6).
86. Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in alcoholic liver disease. Annu Rev Nutr. 2012;32:343–68.
87. Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, et al. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med. 2001;31(12):1544–9.
88. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–56.
89. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol. 2014;11(6):350–61.
90. Kornek M, Popov Y, Libermann TA, Afdhal NH, Schuppan D. Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology. 2011;53(1):230–42.
91. Povero D, Eguchi A, Niesman IR, Andronikou N, de Mollerat du Jeu X, Mulya A, et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal. 2013;6(296):ra88.
92. Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, et al. Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol. 2015. doi: 10.1016/j.jhep.2015.11.020 (Epub ahead of print).
93. Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167(10):5887–94.
94. Degryse B, Bonaldi T, Scaffidi P, Müller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol. 2001;152(6):1197–206.
95. Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54(5):1620–30.
96. Majumdar M, Ratho R, Chawla Y, Singh MP. High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E. Liver Int. 2013;33(9):1341–8.
97. Seo YS, Kwon JH, Yaqoob U, Yang L, De Assuncao TM, Simonetto DA, et al. HMGB1 recruits hepatic stellate cells and liver endothelial cells to sites of ethanol-induced parenchymal cell injury. Am J Physiol Gastrointest Liver Physiol. 2013;305(11):G838–48.